Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Gracell Biotechnologies Inc. GRCL
$2.06
+$0.01 (0.24%)
На 18:03, 12 мая 2023
+191.26%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
140847616.00000000
-
week52high
5.69
-
week52low
1.40
-
Revenue
0
-
P/E TTM
-2
-
Beta
-1.83213700
-
EPS
-1.37000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:00
Описание компании
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Overweight | 01 июн 2022 г. | |
| BTIG | Buy | 04 апр 2022 г. | |
| Citigroup | Buy | 03 февр 2021 г. | |
| Wells Fargo | Overweight | 02 февр 2021 г. | |
| Piper Sandler | Overweight | 02 февр 2021 г. | |
| Citigroup | Buy | 22 сент 2022 г. | |
| HC Wainwright & Co. | Buy | 08 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Penny Stocks To Buy: 4 To Watch With Big News In February
PennyStocks
03 февр 2023 г. в 09:31
Penny stocks with news to watch this week. The post Penny Stocks To Buy: 4 To Watch With Big News In February appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
7 Cheap But Risky Biotech Stocks
Barrons
18 янв 2023 г. в 13:58
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
Gracell Biotechnologies Inc. (GRCL) Q3 2022 Results - Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 12:28
Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q3 2022 Results Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Kevin Yili Xie - Chief Financial Officer William Wei Cao - Founder, Chairman, and Chief Executive Officer Wendy Li - Chief Medical Officer Conference Call Participants Carly Kenselaar - Citigroup Dev Prasad - Jefferies Joseph Catanzaro - Piper Sandler Justin Zelin - BTIG Suowei Wu - Cantor Fitzgerald James Shin - Wells Fargo Operator Ladies and gentlemen, thank you for standing by. Welcome to Gracell Biotechnologies Third Quarter 2022 Conference Call.
Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition
PRNewsWire
03 ноя 2022 г. в 09:10
BCMA/CD19 dual-targeting FasTCAR-T GC012F demonstrated 100% ORR and 100% MRD negativity in the 13 patients treated SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , Nov. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the first clinical data of its ongoing Phase 1, investigator-initiated study in China evaluating FasTCAR-enabled GC012F in newly diagnosed, transplant-eligible, high-risk multiple myeloma (NDMM) patients.
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
PRNewsWire
14 сент 2022 г. в 08:30
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China , Sept.